Loading...
•
Mar 31, 2024
Edgewise Therapeutics Q1 2024 Earnings Report
Reported financial results for the first quarter of 2024 and provided recent business highlights.
Key Takeaways
Edgewise Therapeutics reported positive two-year topline results from the ARCH open label trial and advanced the GRAND CANYON pivotal cohort in Becker. The company also initiated the Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with obstructive HCM.
Announced positive two-year topline results of sevasemten ARCH open label trial and advanced GRAND CANYON pivotal cohort in Becker.
Reported positive interim topline data for DUNE trial of sevasemten in Becker.
Expanded Phase 2 LYNX trial of sevasemten in Duchenne.
Initiated Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with obstructive HCM.